139 related articles for article (PubMed ID: 19060352)
1. Imatinib-induced interstitial lung disease and sunitinib-associated intra-tumour haemorrhage.
Loong HH; Yeo W
Hong Kong Med J; 2008 Dec; 14(6):495-8. PubMed ID: 19060352
[TBL] [Abstract][Full Text] [Related]
2. Acne rosacea associated imatinib mesylate in a gastrointestinal stromal tumor patient.
Demirci U; Coskun U; Erdem O; Ozturk B; Bilge Yilmaz I; Benekli M; Buyukberber S
J Oncol Pharm Pract; 2011 Sep; 17(3):285-7. PubMed ID: 20551113
[TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate-induced acute hepatitis in a patient treated for gastrointestinal stromal tumour.
Pariente A; Etcharry F; Cales V; Laborde Y; Ferrari S; Biour M
Eur J Gastroenterol Hepatol; 2006 Jul; 18(7):785-7. PubMed ID: 16772838
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy and safety of sunitinib after imatinib failure in Japanese patients with gastrointestinal stromal tumor.
Matsumoto K; Sawaki A; Mizuno N; Hara K; Hijioka S; Niwa Y; Tajika M; Kawai H; Kondo S; Yamao K
Jpn J Clin Oncol; 2011 Jan; 41(1):57-62. PubMed ID: 20858619
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.
Demetri GD; van Oosterom AT; Garrett CR; Blackstein ME; Shah MH; Verweij J; McArthur G; Judson IR; Heinrich MC; Morgan JA; Desai J; Fletcher CD; George S; Bello CL; Huang X; Baum CM; Casali PG
Lancet; 2006 Oct; 368(9544):1329-38. PubMed ID: 17046465
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapies in the treatment of GIST: Adverse events and maximising the benefits of sunitinib through proactive therapy management.
Wolter P; Schöffski P
Acta Oncol; 2010; 49(1):13-23. PubMed ID: 19900123
[TBL] [Abstract][Full Text] [Related]
7. [Resistance against tyrosine kinase inhibitors in the treatment of GIST. New therapeutic possibilities appear].
Ahlman H; Nilsson O; Nilsson B
Lakartidningen; 2009 Dec 9-21; 106(50-51):3424-9. PubMed ID: 20180446
[No Abstract] [Full Text] [Related]
8. Sunitinib: new drug. For some gastrointestinal stromal tumours.
Prescrire Int; 2007 Aug; 16(90):138-41. PubMed ID: 17724833
[TBL] [Abstract][Full Text] [Related]
9. Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors.
Tonyali O; Coskun U; Yildiz R; Karakan T; Demirci U; Akyurek N; Benekli M; Buyukberber S
Med Oncol; 2010 Sep; 27(3):768-73. PubMed ID: 19662540
[TBL] [Abstract][Full Text] [Related]
10. Current and future management of GIST.
Blanke C
Clin Adv Hematol Oncol; 2006 Aug; 4(8):582-3. PubMed ID: 17099615
[No Abstract] [Full Text] [Related]
11. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib.
Montemurro M; Schöffski P; Reichardt P; Gelderblom H; Schütte J; Hartmann JT; von Moos R; Seddon B; Joensuu H; Wendtner CM; Weber E; Grünwald V; Roth A; Leyvraz S
Eur J Cancer; 2009 Sep; 45(13):2293-7. PubMed ID: 19467857
[TBL] [Abstract][Full Text] [Related]
12. Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate.
Ohnishi K; Sakai F; Kudoh S; Ohno R
Leukemia; 2006 Jun; 20(6):1162-4. PubMed ID: 16598305
[No Abstract] [Full Text] [Related]
13. [A case of gastrointestinal stromal tumor (GIST) successfully treated with resection after a long-term control medication by molecular targeted drugs].
Inoue Y; Yoshino S; Suzuki N; Hazama S; Oka M
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2378-80. PubMed ID: 22202388
[TBL] [Abstract][Full Text] [Related]
14. Perforation of the colon by invading recurrent gastrointestinal stromal tumors during sunitinib treatment.
Hur H; Park AR; Jee SB; Jung SE; Kim W; Jeon HM
World J Gastroenterol; 2008 Oct; 14(39):6096-9. PubMed ID: 18932293
[TBL] [Abstract][Full Text] [Related]
15. Surgical resection of residual disease in initially inoperable imatinib-resistant/intolerant gastrointestinal stromal tumor treated with sunitinib.
Ruka W; Rutkowski P; Szawłowski A; Nowecki Z; Debiec-Rychter M; Grzesiakowska U; Dziewirski W; Siedlecki JA; Michej W
Eur J Surg Oncol; 2009 Jan; 35(1):87-91. PubMed ID: 18289826
[TBL] [Abstract][Full Text] [Related]
16. Lymphomatoid granulomatosis in a patient previously diagnosed with a gastrointestinal stromal tumour and treated with imatinib.
Salmons N; Gregg RJ; Pallalau A; Woolhouse I; Geh I; Tanière P
J Clin Pathol; 2007 Feb; 60(2):199-201. PubMed ID: 17264244
[No Abstract] [Full Text] [Related]
17. Imatinib mesylate-induced interstitial pneumonitis.
Ma CX; Hobday TJ; Jett JR
Mayo Clin Proc; 2003 Dec; 78(12):1578-9. PubMed ID: 14661689
[No Abstract] [Full Text] [Related]
18. [A rare complication of imatinib mesylate therapy: drug-induced pneumonitis].
Stakhina OV; Turkina AG; Kostina IE; Kochkareva IuB
Ter Arkh; 2010; 82(2):59-61. PubMed ID: 20387680
[TBL] [Abstract][Full Text] [Related]
19. Reversible drug-induced interstitial pneumonitis following imatinib mesylate therapy.
Rajda J; Phatak PD
Am J Hematol; 2005 May; 79(1):80-1. PubMed ID: 15849772
[No Abstract] [Full Text] [Related]
20. Gastrointestinal stromal tumour.
Rubin BP; Heinrich MC; Corless CL
Lancet; 2007 May; 369(9574):1731-41. PubMed ID: 17512858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
